Indonesia Hosts the 26th DCVMN Annual General Meeting 2025, Bio Farma and DCVMN Strengthen Global Collaboration for Health Resilience

Bandung, October 17, 2025 — Indonesia once again takes the global stage in advancing public health. Through PT Bio Farma (Persero), the country has been entrusted to co-host the 26th Developing Countries Vaccine Manufacturers Network (DCVMN) Annual General Meeting (AGM), which will take place on October 29–31, 2025, at The Meru Sanur, Bali.

As co-host and one of DCVMN’s founding members, Bio Farma reaffirms its commitment to strengthening vaccine self-reliance and global health resilience, in line with DCVMN’s mission to advance public health.

DCVMN is a global network comprising 46 vaccine manufacturers from 17 countries across Asia, Africa, Europe, and Latin America, including Argentina, Bangladesh, Brazil, China, Ghana, India, Indonesia, Saudi Arabia, Senegal, Serbia, South Africa, South Korea, Thailand, and Vietnam. Established in 2000, DCVMN aims to strengthen the capacity of vaccine manufacturers in developing countries through advocacy, fostering collaborations, increasing wallet share and professional training on technology advancement, research and development, and knowledge transfer.

President Director of Bio Farma, Shadiq Akasya, stated that hosting the 26th DCVMN AGM in Indonesia is a key opportunity to strengthen collaboration among global vaccine producers.

“As co-host and an active member of DCVMN, Bio Farma is committed to making this forum a platform for strategic synergy among members. Through this meeting, we aim to highlight Indonesia’s concrete contribution in building a global vaccine ecosystem that is innovative, sustainable, and equitable,” said Shadiq.

Meanwhile, Adriansjah Azhari, Chair of the DCVMN Board, emphasized the importance of cross-country collaboration in strengthening global immunization systems.

“With the theme ‘Advancing Innovation & Building Resilient Vaccine Ecosystem for a Safer World,’ the 26th DCVMN AGM will serve as a strategic forum to accelerate innovation among vaccine manufacturers in developing countries. We believe that only through strong global partnerships can the world achieve a more robust and equitable immunization system for all,” he said.

Speaking on the occasion, Rajinder Suri, CEO-DCVMN said, “It is both a pleasure and honour for us to co-host the AGM in the holi city of Bali, Indonesia, with our renowned member company PT BioFarma, a trusted partner from the very inception! We are looking forward for many strategic decisions and collaborations during this AGM leading to better preparedness of the world against any future public health emergency of international concern.”

The international meeting will bring together more than 350 participants, including global vaccine industry leaders, regulators, researchers, and representatives from WHO, UNICEF, GAVI, CEPI, PATH, CHAI, and the Gates Foundation, as well as key stakeholders from both national and international health sectors.

Through this event, Bio Farma and DCVMN reaffirm their shared commitment to strengthening collaboration, fostering innovation, and building a sustainable global health system that ensures equitable vaccine access for all.

About DCVMN

The Developing Countries Vaccine Manufacturers Network (DCVMN) is a global alliance of 46 vaccine manufacturers from 17 developing countries, established in 2000 to strengthen public health through equitable access to high-quality vaccines. DCVMN promotes collaboration among its members through advocacy, capacity building, professional training, and joint research initiatives, aimed at enhancing global immunization programs.

Working closely with international organizations such as WHO, UNICEF, GAVI, CEPI, PATH, CHAI, and the Gates Foundation, DCVMN strives to ensure that every nation has the capability to produce and supply affordable, life-saving vaccines. For further information, please visit dcvmn.org.

About Bio Farma

PT Bio Farma (Persero) is Indonesia’s state-owned life science company and the largest vaccine manufacturer in Southeast Asia. Founded in 1890 and headquartered in Bandung, Bio Farma produces and supplies vaccines to more than 150 countries, while playing an active role in biotechnology research, innovation, and global health security.

As a member of DCVMN, Bio Farma continues to contribute to international collaboration to ensure equitable vaccine access and improved global public health. For further information, please visit www.biofarma.co.id.